LuciCapma contains capmatinib, a targeted therapy used in the treatment of certain types of non-small cell lung cancer (NSCLC). It is specifically prescribed for patients whose cancer is associated with MET gene alterations. This medication is used globally in oncology practice for personalized cancer treatment.
Active Ingredient
Capmatinib is a MET inhibitor that targets abnormal signaling pathways responsible for cancer cell growth. It blocks the MET receptor tyrosine kinase, helping to slow tumor progression.
Uses of LuciCapma
• Treatment of metastatic non-small cell lung cancer
• MET exon 14 skipping mutation-positive NSCLC
How LuciCapma Works
Capmatinib inhibits MET receptor signaling pathways, which are often overactive in certain lung cancers. By blocking this pathway, it reduces cancer cell growth and spread.
How to Use LuciCapma
• Take as prescribed by a healthcare professional
• Usually taken orally with or without food
• Follow dosage instructions carefully
Possible Side Effects
• Nausea
• Fatigue
• Peripheral edema
• Vomiting
Precautions
• Monitor liver function
• Avoid during pregnancy
• Inform doctor about all medications
Safety Information
Use only under medical supervision. Regular monitoring is required to assess response and side effects.
Storage
• Store at room temperature
• Protect from moisture and sunlight
• Keep out of reach of children
